AtriCure, Inc.

Listed Company

ATRCCIK 0001323885NasdaqLarge AcceleratedSurgical & Medical Instruments & ApparatusDelawareFY ends Dec 31

Period

FY 2025

Revenue

$534.53M

Net Income

$-11.45M

Total Assets

$654.18M

Equity

$491.94M

Shares Out

50.64M

Op. Cash Flow

$57.33M

ATRC$34.90+17.23% · past yearDBEQ Basic

Daily closing prices

Business

AtriCure is a leading innovator in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management. The company manufactures and sells ablation devices (radiofrequency and cryogenic), left atrial appendage exclusion systems, and cryoablation probes for nerve block therapy. Products are sold directly in the United States, Germany, France, United Kingdom, Benelux, Australia and Canada, with international distribution through third-party distributors in other markets.

Summary from 10-K filed 2026-02-19

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	535	465	399	330	274
Cost of revenue	134	118	99	84	68
Gross profit	401	348	300	246	206
Research and development expenses	99	96	74	57	49
Selling, general and administrative expenses	311	291	253	231	205
Total operating expenses	410	388	327	289	151
Loss from operations	−9	−40	−27	−43	55
Interest expense	−6	−6	−7	−5	—
Interest income	4	4	4	2	466,000
Loss on debt extinguishment	0	−1	0	0	—
Other income (expense)	683,000	−326,000	−31,000	−537,000	−366,000
Loss before income tax expense	−10	−44	−30	−46	50
Income tax expense	1	1	591,000	268,000	188,000
Net loss	−11	−45	−30	−46	50
Basic net loss per share (in usd per share)	−0.24	−0.95	−0.66	−1.02	1.11
Diluted net loss per share (in usd per share)	−0.24	−0.95	−0.66	−1.02	1.09
Weighted average shares outstanding, basic (in shares)	48	47	46	46	45
Weighted average shares outstanding, diluted (in shares)	48	47	46	46	46
Unrealized gain on investments	0	800,000	3	−3	−941,000
Foreign currency translation adjustment	2	−842,000	205,000	−337,000	−319,000
Other comprehensive income (loss)	2	−42,000	3	−3	−1
Comprehensive loss, net of tax	−10	−45	−27	−50	49

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	167	123	84	58	44
Accounts receivable, less allowance for credit losses of $750 and $550	67	60	53	43	33
Inventories	78	75	68	46	39
Prepaid and other current assets	10	9	9	5	5
Total current assets	323	268	266	215	196
Property and equipment, net	39	42	42	39	31
Operating lease right-of-use assets	7	6	4	4	5
Intangible assets, net	48	56	64	39	43
Goodwill	235	235	235	235	235
Other noncurrent assets	3	3	2	2	955,000
Total Assets	654	609	614	585	615
Accounts payable	25	25	27	20	19
Accrued liabilities	53	46	45	33	36
Other current liabilities	3	3	—	5	2
Total current liabilities	82	73	75	58	56
Long-term debt	62	62	61	57	60
Finance and operating lease liabilities	12	12	11	—	—
Other noncurrent liabilities	7	1	1	1	1
Total Liabilities	162	148	148	129	132
Commitments and contingencies (Note 10)	—	—	—	—	—
Common stock, $0.001 par value, 90,000 shares authorized; 49,792 and 48,869 issued and outstanding	50,000	49,000	48,000	47,000	46,000
Additional paid-in capital	905	864	824	787	765
Accumulated other comprehensive income (loss)	566,000	−1	−993,000	−4	−948,000
Accumulated deficit	−413	−402	−357	−327	−280
Total Stockholders Equity	492	461	466	457	484
Total Liabilities and Stockholders Equity	654	609	614	585	615

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Share-based compensation expense	45	40	36	29	28
Depreciation	12	11	9	8	8
Amortization of intangible assets	8	8	5	4	3
Amortization of deferred financing costs	478,000	478,000	486,000	507,000	759,000
Amortization of investments	0	107,000	632,000	1	2
Acquired in-process research and development expense	6	12	0	0	—
Other non-cash adjustments	1	2	2	739,000	2
Accounts receivable	−6	−8	−10	−9	−10
Inventories	−2	−8	−22	−7	−4
Other current assets	−328,000	−949,000	−3	−515,000	−700,000
Accounts payable	−960,000	−2	6	3	5
Accrued liabilities	7	1	12	−3	8
Other noncurrent assets and liabilities	−2	−1	−1	−2	−3
Net cash provided by operating activities	57	12	4	−22	−14
Sales and maturities of available-for-sale securities	0	54	64	86	206
Purchases of property and equipment	−9	−11	−12	−17	−10
Proceeds from sale of property and equipment	0	25,000	0	0	0
Acquisitions, including in-process research and development	−6	−12	−30	—	—
Proceeds from capital grant	500,000	0	0	—	—
Net cash (used in) provided by investing activities	−15	30	22	44	24
Proceeds from revolving credit facility, net of financing costs	0	61	0	0	5
Payments on debt, leases and financing obligation	−1	−63	−992,000	−899,000	−6
Proceeds from financing obligation	6	0	0	—	—
Payment of financing costs and bank fees	0	−1	−60,000	0	−1
Proceeds from stock option exercises	1	1	2	2	8
Shares repurchased for payment of taxes on stock awards	−11	−7	−7	−12	−18
Proceeds from issuance of common stock under employee stock purchase plan	6	5	5	4	4
Net cash provided by (used in) financing activities	1	−4	−32,000	−7	−8
Effect of exchange rate changes on cash and cash equivalents	747,000	−424,000	−58,000	−361,000	−372,000
Net increase in cash and cash equivalents	45	38	26	14	2
Cash paid for interest	5	6	6	4	4
Cash paid for income taxes, net of refunds	1	619,000	395,000	192,000	190,000
Accrued purchases of property and equipment	1	334,000	1	272,000	2

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is AtriCure, Inc.'s CIK number?

AtriCure, Inc.'s SEC CIK number is 0001323885 (1323885). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find AtriCure, Inc.'s SEC filings?

All of AtriCure, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did AtriCure, Inc. last report earnings?

AtriCure, Inc. (ATRC) most recently filed an earnings 8-K with the SEC on May 5, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001323885-26-000018). This is AtriCure, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is AtriCure, Inc.'s most recent earnings 8-K?

AtriCure, Inc.'s latest earnings 8-K (Item 2.02) was filed May 5, 2026 under accession 0001323885-26-000018. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View AtriCure, Inc.'s latest earnings 8-K →
Look up any company's CIK number →